Katie Hebron


Graduate Student at Dr. Zijlstra’s Lab, Vanderbilt University

Kate began her career in research as an undergraduate at Montclair State University in New Jersey. She spent three years in the lab of John Siekierka, Ph.D. studying the contribution of p38 MAPK parasite orthologs to evasion of host innate immunity. After graduating from MSU, she began graduate school at Vanderbilt University and joined Dr. Zijlstra’s laboratory for her dissertation research. She is investigating the regulation of prostate cancer progression by  the cell adhesion molecule, ALCAM. Upon completion of her doctoral training, Kate intends to pursue a career as an independent scientist at an academic research institution.

Relevant Publications

Babaev VR, Hebron KE, Ding L, Zhang Y, May JM, Fazio S, & Linton MF. Macrophage deficiency of Akt2 but not Akt1 reduces atherosclerosis in LDLR null mice. J Lipid Res, 2014 (In Press).

Stoletov K, Bond D, Hebron K, Raha S, Zijlstra A, & Lewis JD Metastasis as a therapeutic target in prostate cancer: a conceptual framework. Am J Clin Exp Urol, 2014  2(1):45-56 (Review).

Palmer TD, Martínez CH, Vasquez C, Jones-Paris CR, Hebron KE, Chan SM, Chalasani V, Gomez-Lemus JA, Williams AK, Chin JL, Ketova T, Lewis JD, & Zijlstra A. Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression.  Can Res, Jan 2014 vol. 74 (1):173-87.

Patel A, Chojnowski AN, Gaskill KE, DiMartini W, Goldberg R, Siekierka J. The role of a Brugia malayi p38 MAP kinase ortholog (Bm-MPK1) in parasite antioxidative stress responses. Mol Biochem Parasitol, 2011 vol.
176 (2): 90-97.